文献速递鼻科

中国人群尘螨皮下免疫治疗过敏性鼻炎的疗效预测方法:一项前瞻性研究

Predictive methods for efficacy of house dust mite subcutaneous immunotherapy in allergic rhinitis patients: a prospective study in a Chinese population.
PubMed 文献 · Int Forum Allergy Rhinol · 2019-12-23

该前瞻性研究纳入119例接受2年标准化尘螨皮下免疫治疗的过敏性鼻炎患者,在第4、6、12、18个月评估临床特征、皮肤点刺试验及治疗反应。结果显示第2年末总体有效率为67.4%,第4、6、12、18个月的疗效均与第24个月疗效显著相关,早期(第4个月)疗效可预测第2年疗效。

要点

  • 第4个月疗效即可预测第2年皮下免疫治疗疗效。
  • 第2年末总体有效率为67.4%。
  • 年龄、性别、哮喘、BMI、吸烟史及变应原类别与疗效无关。

核心结论

  • 尘螨皮下免疫治疗第4、6、12、18个月的疗效与第24个月疗效强相关。
  • 第4个月疗效即可预测第2年疗效,有助于判断是否需要长期治疗。

研究设计与样本

  • 前瞻性研究,纳入119例接受2年标准化尘螨皮下免疫治疗的过敏性鼻炎患者。
  • 在第4、6、12、18个月评估临床特征、皮肤点刺试验反应和治疗反应。

主要发现

  • 第2年末免疫治疗总体有效率为67.4%。
  • 年龄、性别、哮喘、体重指数、吸烟史和气传变应原类别与免疫治疗疗效无关。
  • 第4个月疗效与第24个月疗效相关(OR=4.250;p=0.004)。
  • 第6个月疗效与第24个月疗效相关(OR=10.476;p<0.000)。
  • 第12个月疗效与第24个月疗效相关(OR=18.000;p<0.000);第18个月疗效与第24个月疗效相关(OR=9.716;p<0.000)。

关键数值与推荐

  • 有效免疫治疗定义为第2年免疫治疗结束时平均调整症状评分(AAdSS)较基线下降25%。
  • 第4、6、12、18个月改善的曲线下面积分别为0.805、0.834、0.837、0.854。

临床怎么用

  • 可在治疗第4个月评估疗效以预测第2年反应,辅助决定是否继续长期治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Allergen-specific immunotherapy (AIT) is the only available treatment that can induce specific immune tolerance to allergens. However, the treatment course lasts >3 years, and there is no reliable method to predict treatment response. Therefore, in this study we aimed to establish a method that can predict treatment response to AIT in the second year. METHODS: This prospective study enrolled 119 patients who had undergone 2-years of standard-quality house dust mite subcutaneous immunotherapy. Clinical characteristics, skin-prick test response, and treatment response were evaluated at months 4, 6, 12, and 18. Effective AIT was defined as a 25% reduction in average adjusted symptom score (AAdSS) from baseline at the end of the second year of immunotherapy. RESULTS: The overall efficacy rate at the end of year 2 of the AIT was 67.4%. Age, sex, asthma, body mass index, smoking history, and aeroallergen categories were not associated with efficacy of AIT. Meanwhile, efficacy data at month 4 (odds ratio [OR], 4.250; p = 0.004), month 6 (OR, 10.476; p < 0.000), month 12 (OR, 18.000; p < 0.000), and month 18 (OR, 9.716; p < 0.000) were associated with month 24 efficacy. The area under the curve for improvement at 4, 6, 12, and 18 months was 0.805, 0.834, 0.837, and 0.854, respectively. CONCLUSION: Efficacy of AIT at months 4, 6, 12, and 18 is strongly associated with efficacy at month 24. Efficacy as early as month 4 can predict efficacy at the second year, and this may help to determine the need for long-term treatment. Our findings may be useful for identifying novel treatment strategies for AIT.

来源:Int Forum Allergy Rhinol,查看原文。版权归原作者所有。

引用

  1. Liu Z, Lu H, Feng X, et al. Predictive methods for efficacy of house dust mite subcutaneous immunotherapy in allergic rhinitis patients: a prospective study in a Chinese population. Int Forum Allergy Rhinol. 2019. PMID: 31869861. doi:10.1002/alr.22508

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。